Stock 460 SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Sihuan Pharmaceutical Holdings Group Ltd.

Equities

460

BMG8162K1137

Market Closed - Hong Kong S.E.
Other stock markets
 09:09:00 03/05/2024 BST 		5-day change 1st Jan Change
0.61 HKD -3.17% Intraday chart for Sihuan Pharmaceutical Holdings Group Ltd. +8.93% -6.15%
05-02 Sihuan Pharmaceutical Unit's Lung Cancer Drug NDA Accepted by NMPA, Stocks Shoot Over 10% MT
04-25 Sihuan Pharma Unit Wins Bid to Supply Insulin Products to Chinese Government MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sihuan Pharmaceutical Unit's Lung Cancer Drug NDA Accepted by NMPA, Stocks Shoot Over 10%
Sihuan Pharma Unit Wins Bid to Supply Insulin Products to Chinese Government
Sihuan Pharmaceutical Narrows 2023 Loss on Absence of Asset, Investment Impairments
Sihuan Pharmaceutical Holdings Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Sihuan Pharmaceutical's RF Device Wins Registration Approval in China
Sihuan Pharmaceutical Holdings Unit Forms Consortium for Ji Yao Restructuring
China Approves Drug Registration for Sihuan Pharmaceutical Unit's Type 2 Diabetes Drug
Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets
China Includes Four Injectables by Sihuan Pharma Associate in Drug Reimbursement List; Shares Rise 3%
China Grants Registration Approval to Sihuan Pharmaceutical's Insulin Products
Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes
China's Medical Products Administrator Approves Sihuan Pharma Unit's Diabetes Drug
National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical
China Accepts New Drug Application of Sihuan Pharmaceutical Subsidiary's Breast Cancer Treatment
China Accepts New Drug Application for Sihuan Pharmaceutical Unit's Breast Cancer Tablets
Sihuan Pharmaceutical Swings to H1 Loss
Sihuan Pharmaceutical Holdings Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Sihuan Pharmaceutical's Revenue to Drop 30% in H1
Sihuan Pharmaceutical Holdings Group Ltd. Provides Unaudited Consolidated Guidance for the Six Months Ended 30 June 2023
China Approves Sihuan Unit's Clinical Trial for Diabetes Injections; Shares Fall 3%
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 460 Stock
  4. News Sihuan Pharmaceutical Holdings Group Ltd.
  5. Other languages